Author:
Hoffmann Johannes J. M. L.,Kops Oliver
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Hematology
Reference13 articles.
1. Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss AJ. D-Phe-Pro-Arg-chloromethylketone: Its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemost 1986;56:160–164.
2. Verstraete M, Bounameaux H, de Cock F, Van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985;235:506–512.
3. {Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, Thornton D, Collen D. Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. Thromb Res 1988;50:121–133.
4. Seifried E, Tanswell P. Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thromb Haemost 1987;58:921–926.
5. Hoffmann JJ, Vijgen M. Prevention of in vitro fibrinogenolysis during laboratory monitoring of thrombolytic therapy with streptokinase or APSAC. Blood Coagul Fibrinolysis 1991;2:279–284.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献